An investigation of cellular components released from human renal cancer and foetal kidney xenografts in nude mice (nu/nu) by cross-immunization of hairy littermate relatives. by Matthews, P. N. et al.
Br. J. Cancer (1984), 49, 193-198
An investigation of cellular components released from
human renal cancer and foetal kidney xenografts in nude
mice (nu/nu) by cross-immunization of hairy littermate
relatives
P.N. Matthews*, J. Hermon-Taylor & A.G. Grant
Department ofSurgery, St. George's Hospital Medical School, Cranmer Terrace, London SWJ7 ORE
Summary The release of components from human kidney tumour xenografts (GYL) and human foetal
kidney explants maintained in nude mice has been studied. The GYL tumour released antigens into the serum
which could be detected by the generation of antibodies following cross-immunisation of closely related hairy
litter mate (HLM) mice. The production of anti-GYL antibody was monitored by an 1125 binding assay using
viable GYL tumour cells. In 2/16 hairy litter mate mice, cell surface antibody binding by GYL cells was twice
that found with 8 other human tumour cell lines (including 2 other kidney cancer cell lines). Absorption of
these antisera with 107 GYL tumour cells completely abolished this response, where 50%, 38% and 25% of
activity remained following absorption with; a normal kidney cell line, a homogenate of normal kidney and a
mixed pool of human tumour cells. Six out of 8 GYL tumour bearing nude mice tested had elevated plasma
levels of HCG. Absorption of the HLM antisera with an excess of commercial HCG abrogated 1125 binding
by only 15%, suggesting that antibody production was not directed primarily against ectopic HCG.
There has been considerable interest in the
immunobiology of human cancers since the
demonstration of both cellular and humoral
immunity to neuroblastomas (Hellstrom et al.,
1968). Evidence that human renal cancers may be
influenced by the hosts' own immune system is
thought to be provided by occasional reports of the
spontaneous regression of metastases following
surgical excision of a primary kidney tumour
(Freed et al., 1977) and antibodies directed against
human renal cancer have been detected in the
serum of some patients with this disease
(Ackerman, 1975; Dekernion et al., 1979; Ueda et
al., 1981). However, the concept that human
tumour cells may display type specific determinants
which are probably only weakly antigenic
(Herberman et al., 1977), has never been
convincingly demonstrated.
The development of the nude mouse as a host for
human tumours has made it possible to study many
human cancers in vivo and it has been shown that
human kidney tumours xenografted into nude mice
retain morphological and behavioural features of
the original tumour (Katsuoka et al., 1976;
Matthews et al., 1982). Several investigators have
shown that human tumours growing as xenografts
in nude mice retain their ability to release tumour
products such as carcinoembryonic antigen (Sordat
et al., 1974), human chorionic gonadatropin
(Kameya et al., 1976) and B2 microglobulin
(Dipersio et al., 1980).
The purpose of this study was to investigate the
release of cellular components from xenografted
human kidney tumours by using the nude mouse
hairy litter mate model previously developed for the
study of pancreatic cancer (Grant & Duke, 1981).
Materials and methods
Animals
Outbred congenitally athymic nude mice (nu/nu)
and their related hairy litter mates [HLM] (nu/+)
were obtained from the Imperial Cancer Research
Fund Laboratories (Mill Hill, UK) when aged 4-6
weeks. The nude animals were maintained on sterile
diet in negative pressure isolators, while the HLM
mice were housed conventionally.
Xenografts
A human kidney tumour was established as a
xenograft (GYL) in nude mice as previously
described (Matthews et al., 1982). Xenografted
tumours were grown in 75 nude mice and on
reaching a size of 1.5cms diameter the mice were
exsanguinated by cardiac puncture and the resulting
serum (30ml) pooled and stored at -70°. A total
©) The Macmillan Press Ltd., 1984
Correspondence: A.G. Grant
*Present address: Department of Urology, Charing
Cross Hospital, London SW6.
Received 8 August 1983; accepted 27 October 1983.194 P.N. MATTHEWS et al.
of 35 human foetal kidneys (8-14 weeks gestation)
obtained from the tissue bank at the Royal
Marsden Hospital (London) were minced and
injected subcutaneously into 40 nude mice. Prior to
regression of the s.c. nodules that formed (4-6
weeks), mice were exsanguinated, the serum pooled
and the nodule examined histologically.
Tissue culture
Cell lines from kidney tumours GYL and WIL
(Matthews et al., 1982), colonic cancer CAS
(Davies et al., 1981) and pancreatic cancer WAD
were established in this laboratory from tumour
xenografted into nude mice; GER was established
directly from a primary pancreatic cancer explant
(Grant et al., 1979); CAKI-1, a kidney tumour
(Fogh & Trempe, 1975) and RT4, a bladder
tumour (Rigby & Franks, 1970) were kindly
supplied by Drs. Fogh and Franks respectively. A
colonic tumour HT29 (Fogh & Trempe, 1975) and
breast cancer "MDA 157" (Young et al., 1974)
were also available for study. Normal human
kidney tissue, obtained at surgery, was finely
minced with crossed scalpels, trypsinized with
0.25% trypsin at 370 for 1 h to provide a short term
cell culture of normal tissue. All cell lines were
maintained in Hams F12 medium supplemented
with 10% foetal bovine serum and harvested with
0.02% EDTA in calcium and magnesium free
Earle's medium (Flow Laboratories, UK).
Immunisation ofimmune-competent mice
Pooled serum from the GYL kidney tumour
bearing nude mice was used to immunise 16 HLM
mice. A further 8 HLM mice were immunised with
serum from non-tumour bearing nude mice. All
animals were individually marked. Each HLM
mouse was inoculated s.c. at 4 separate sites with
0.4ml of serum emulsified with an equal quantity
of complete Freunds adjuvant on Day 0 and Day
14. Further subcutaneous inoculations using 0.4ml
of serum alone were carried out on Day 28, Day 42
and Day 61. Tail vein blood samples were taken
prior to immunisation and following the 3rd, 4th
and final inoculations to test for antibody. Using
the same immunisation regime, serum from human
foetal kindey bearing nude mice was used to
immunise 6 HLM mice. Mouse antihuman
lymphocyte serum was prepared as described
previously (Grant & Duke, 1981).
Carcino-embryonic antigen (CEA), alpha-fetoprotein
(AFP), beta-chorionic gonadotropin (HCG),
parathyroid hormone (PTH) and renin estimations
Plasma levels of CEA, AFP and HGC were
measured by the department of Medical Oncology
at the Charing Cross Hospital, London (Bagshawe
et al., 1971) in 8 GYL kidney tumour bearing nude
mice and 8 normal nude mice. Plasma PTH
estimations were carried out in the department of
Clinical Pathology at St. George's Hospital,
London using a method described by Woo &
Singer (1974) and modified to use a second
antibody separation of bound and free PTH
fractions (J. Nesbitt - unprinted data) in 6 GYL
kidney tumour bearing nude mice and 6 normal
nude mice. Plasma renin levels were measured by
Dr. N. Payne at the Cobbold Laboratories, the
Middlesex Hospital, London.
PI25-antibody binding assay
The presence of antibodies directed against viable
tumour cells was detected by an indirect 1125
binding assay (Grant & Duke, 1981) in sera (20 x
diluted) from both nude mice and HLM mice.
Binding between HLM mouse antisera and GYL
cells was compared to binding between HLM
antisera and a panel of 8 other cell lines; the results
were expressed as a binding ratio. A ratio of 2 or
more was considered to be significant. Antiserum
from HLM mice immunised with normal nude
mouse serum was used to detect non-specific
binding and served as a negative control while
measurement of binding between all the target line
cells and antihuman lymphocyte serum provided a
positive control.
Antisera were absorbed with:- 5 x 105 to 1.6 x 107
viable cell suspensions, 21-207mg of normal kidney
homogenate insolubilised in 2.5% gluteraldehyde in
PBS or 0.001-10iu of a commercially available
preparation of HCG (Profasi-Serona Laboratories
(UK) Ltd.) for 60min at room temperature, prior
to the antibody binding assay.
Results
Production ofantibody
No free antibody to GYL cells was detected in the
sera of 10 GYL tumour bearing nude mice.
Antibody production throughout the period of
immunisation of the HLM mice was monitored by
1125 binding assay in 4 test mice and 4 control mice
[Figure 1]. Having demonstrated a sustained rise in
antibody levels, all 24 mice were sacrificed and
individual sera tested against the GYL kidney
tumour cell line. Mice immunised with HLM serum
had significantly higher levels (P= <0.01) of
antibody directed against GYL cells than those
immunised with normal nude mouse serum [FigureANTIBODIES TO RENAL TUMOUR XENOGRAFTS 195
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Figure 1 The development of antibodies binding to
the surface of human renal cancer cells (GYL) during
immunisation of HLM mice (nu/+). Test mice (@-
-@) repeatedly challenged with serum from human
kidney tumour bearing nude mice relatives (nu/nu).
Mean of 4 control mice challenged with normal nude
mouse serum (0 O).
2]. Individual sera were then tested against a panel
of 8 human tumour cell lines. Antisera from 11 of
the HLM mice bound more strongly to the GYL
cells than any of the panel of other cell lines and in
2 of thcsc HLM mice the binding ratio was greater
than 2 in comparison with all of the other cell
lines [Figure 3]. Binding of antihuman lymphocyte
sera with GYL, WIL, CAKI-1 or RT4 cells gave
readings ranging from 14,000-17,000 cpm per
5 x105 cells.
Foetal kidney
Following s.c. injection of human foetal kidney
tissue a small nodule grew slowly for 4-6 weeks,
eventually reaching a size of approximately 6mm
diameter. All nodules regressed after this, but
histological sections taken at 4 weeks confirmed
viable kidney tissue [Figure 4]. We were unable to
detect antibody directed against GYL tumour cells
in any of the HLM mice immunised with the sera
of the nude mice bearing foetal explants.
Figure 2 Binding of individual HLM antisera to
GYL kidney tumour cells at the end of the
immunization schedule: test animals have been
immunised with serum from GYL tumour bearing
nude mice; control animals have been immunised with
normal nude mouse serum.
CEA, AFP, HCG, PTH and renin levels in normal
and tumour bearing nude mice
Table I shows plasma levels of CEA, AFP, HCG,
PTH and renin in the two groups of mice. There
was a significant difference in the plasma HCG
levels of GYL tumour bearing nude mice
(18.6+12.2iuPI and normal nude mice
(6.75 +4.4iu -). Preincubation of antisera with
0.001-10iu of HCG to absorb free antibody to
HCG maximially, reduced binding by only 15%.
Absorption of antisera with tumour cells and normal
kidney
Pre-incubation of HLM antisera with 107 viable
GYL tumour cells completely abolished the
antibody response, while absorption with 1.5 x 107
viable cells from a mixed pool of other tumour cells
(WAD, MDA, GER, CAS, HT-29, RTA, WIL and
CAKI-I left 25% of binding activity remaining
[Figure 5]. Absorption of the antisera with 1.5 x 107
cells derived from normal kidney left 50% of
binding activity whereas absorption with 207mg of
normal kidney homogenate left 38% of binding
activity.
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Figure 3 Binding of HLM antisera (A2) to a panel of
human tumour cell lines (kidney - GYL, CAKI-1,
WIL; bladder - RT4; colon - HT-29, CAS; pancreas -
GER, WAD; breast - MDA). Results (±s.d., 4
experiments) are expressed as 1125 binding per 105 cells
and as a binding ratio of counts bound to kidney
tumour cells over counts bound to other target cells.
Binding of control HLM antisera (2000-2500cpm per
5 x 105 cells) has been subtracted.
Table I Estimations of HCG, CEA, AFP, PTH and renin in nude mouse plasma
Normal nude mice "GYL" tumour bearing nude
No. mice (± s.d.) mice (± s.d.) Significance
HCG 8 6.75+4.4iul-P 18.6+ 12.2iuI1 p= <O.OOJa
CEA 8 34.5+ 13.6ygI -1 25.75+ 15.48upgI 1 NS
AFP 8 22.25+7.7kul-1 18.5+10.75kuI-1 NS
PTH 6 0.315+0.10pgl-1 0.35+0.13pgI-1 NS
Renin 8 14.0+ 1.4pmolh - 1 ml - 1 14.3+ 1.8pmolh - 1 ml -1 NS
aStudent 't' test.
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Figure 4 Histological section (H & E, x400) of
human foetal kidney tissue xenografted into a nude
mouse and maintained for 4 weeks.
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Figure 5 Binding of HLM antisera (A2) to GYL
kidney tumour cells following absorption with: (a)
GYL kidney tumour cells, (b) a mixed pool of other
human tumour cells. Binding counts for control HLM
mice have not been deducted.
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Discussion
Although nude mice have an apparently normal B-
lymphocyte complement (Sprent & Miller, 1972),
we were unable to detect free antibody to the GYL
kidney tumour in the serum of the tumour bearing
nude mice, findings similar to those previously
identified in human pancreatic cancer bearing nude
mice (Grant & Duke, 1981). Cross immunisation of
the closely related immunocompetent hairy litter
mates with serum from the kidney tumour bearing
nudes led to the production of antibodies directed
against the circulating components released from
human tumour cells during growth. While antibody
levels in the HLM mice were at least twice those in
control HLM mice, only 2 of the mice produced
significantly higher anti-GYL antibody levels
(binding ratio >2) when tested against the other 8
human cancer cell lines. This result may reflect the
heterogenicity of the outbred HLM mouse. The two
other renal cancer cell lines (CAKI-1 and WIL) in
the panel did not selectively bind these antisera,
suggesting that the antibodies generated by HLM
were predominantly directed against the GYL
tumour itself. This observation was further
supported by the finding that the absorption of the
antisera with a mixed pool of human tumour cells
(including CAKI-I and WIL kidney cancer cell
line), a normal kidney cell line and a homogenate
of normal kidney did not completely abolish the
antibody response. This implies that some of the
antibody is directed against GYL tumour
components not present on other tumours or
normal kidney.
Kidney tumours have been shown to release a
variety of inappropriate hormones and other
tumour related products (Sufrin et al., 1977;
Chisholm, 1982). Although the GYL tumour did
not secrete CEA, AFP, PTH or renin, 6/8 tumour
bearing nude mice had raised levels of HCG, and
this finding supports clinical evidence that renal
tumours may occasionally secrete HCG (Castleman
et al., 1972; Chilsolm, 1974). Absorption of the
antisera with an excess of commercial HCG
resulted in only a small reduction in antibody
binding, suggesting that the antibody was not
directed primarily against ectopic HCG.
One of the alterations to the cell surface that
may occur during the process of neoplastic
transformation is the re-expression of foetal
antigens (Uriel, 1979). We used the HLM model to
try and compare the release of cell surface
components from xenografted human foetal kidney
tissue with components released by the GYL
tumour. However, in common with other reports of
human foetal tissue xenografted into nude mice, we
found that the foetal kidney tissue would not
maintain over a long period (Povlsen et al., 1974;
Bastert et al., 1977; Usadel et al., 1977). Careful
scrutiny of the histological sections of the foetal
kidney xenografts showed only a very few mitotic
figures compared to the kidney tumour xenografts.
The absence of antibody to the circulating
components of the foetal kidney tissue is probably
related to the small size of the xenograft and to the
paucity of actively dividing cells.
In common with our findings for pancreatic
cancer (Grant & Duke, 1981) this cross-
immunisation technique offers a way of producing
antibodies directed against antigens that are
constantly released from the tumour cell surface.
The spleen cells from these animals are currently
being used to produce monoclonal antibodies in
order to identify and chacterise these antigens.
We are grateful for the financial support of the South
West Thames Regional Health Authority and the Cancer
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